Abstract :
[en] Selection and characterization of anti-NDM-1 nanobodies
Cawez Frédéric1, Mercuri Paola Sandra1, Piccirilli Alessandra3, Perilli Mariagrazia3, Morales Yánez Francisco2, Dumoulin Mireille2 & Galleni Moreno1
Biological Macromolecules1, NEPTUN2, Center for Protein Engineering, InBioS, University of Liege, Belgium; Dept of Biotechnological and Applied Clinical Sciences3 , University of L'Aquila, Italy. The misuses of beta-lactam antibiotics lead to the selection of multidrug-resistant (MDR) bacteria which are unaffected by the presence antibiotics. Therefore, it is essential to develop new rapid diagnostic assays in order to circumvent the nosocomial infections. In addition, it is essential to develop new inhibitor's scaffolds able to block the beta-lactamase activity. To develop new inhibitors, one strategy consists to select VHH antibodies that serve to the development of new beta-lactamase inhibitors by peptidomimetics.
